Zentalis Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Zentalis is a clinical-stage oncology biopharmaceutical company with no products approved for sale and no product-sales revenue.
Financial and operating highlights
| Metric | Q2 2023 | Six months 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $42.7 million | $91.3 million | $43.8 million / $89.9 million |
| Total operating expenses | $103.9 million | $168.9 million | $63.5 million / $121.3 million |
| Net loss attributable to Zentalis | $112.5 million | $175.7 million | $68.4 million / $127.4 million |
| Net loss per share, basic and diluted | $1.85 | $2.93 | $1.34 / $2.64 |
| Net cash used in operating activities | Not separately presented | $128.6 million | $93.2 million |
As of June 30, 2023, cash and cash equivalents were $266.6 million and available-for-sale marketable securities were $286.4 million, totaling approximately $553.0 million. Current assets were $563.9 million and current liabilities $51.8 million. Total liabilities were $98.2 million, including lease liabilities; the company reported no indebtedness. Management said existing cash, cash equivalents and marketable securities were expected to fund operating expenses and capital expenditures into 2026, while cautioning that estimates depend on assumptions and available funds would not cover all activities needed to complete development.
No meaningful operating margin comparison is available because the company has not generated product revenue. The filing does not present product gross margin.
Material changes and unusual items
- Net loss attributable to Zentalis rose to $112.5 million in Q2 from $68.4 million a year earlier, and to $175.7 million for the half-year from $127.4 million. The increases chiefly reflect the Zentera-related acquired in-process R&D charge and a larger loss on the equity-method investment.
- In June, Zentalis terminated its collaboration and license agreements with Zentera, reacquiring Greater China rights to azenosertib, ZN-d5 and ZN-c5 and restoring worldwide rights to those assets. It recorded $45.6 million of in-process R&D expense, including cash and non-cash consideration, and a $13.7 million Q2 loss on the equity-method investment. Consideration included a $30 million upfront payment, forgiveness of $9.4 million in receivables and contingent consideration with an estimated fair value of $0.5 million. Future Greater China sales, if any, carry low-single-digit royalties.
- A June follow-on offering of 11.0 million shares generated approximately $250 million gross proceeds and $235.7 million net proceeds. Shares outstanding were 70.6 million at June 30, versus 59.3 million at December 31, 2022.
- Cash from operations used $128.6 million in the first half, while financing provided $237.0 million, primarily from the offering. Investing activities provided $115.1 million, largely reflecting marketable-security maturities and reinvestment activity.
- The company recorded a $5.0 million operating lease and fixed-asset impairment in the first half after subletting New York office space. It reported no material legal proceedings and no off-balance-sheet arrangements.
Business outlook, programs and risks
- Management expects R&D expenses to increase substantially as clinical trials advance and new studies begin. It expects continuing operating losses and says additional capital will be required; no credit facility or committed external funding source was in place.
- Azenosertib is being studied alone and in combinations. The company selected a monotherapy Phase 2 dose of 400 mg once daily on a five-days-on, two-days-off schedule. Previously reported Phase 1/2 chemotherapy-combination results in platinum-resistant ovarian cancer showed response rates ranging from 19.4% to 50.0% across regimens; these are company-reported clinical findings, not approval evidence. The company planned a Phase 3 study in Cyclin E1-positive platinum-sensitive ovarian cancer with azenosertib plus carboplatin or paclitaxel.
- ZN-d5 remains in clinical trials, including studies in relapsed or refractory light-chain amyloidosis and acute myeloid leukemia. A BCL-xL degrader candidate is in IND-enabling studies.
- Key risks include clinical safety or efficacy failures, delays in enrollment or regulatory review, biomarker and diagnostic uncertainty, dependence on third-party CROs and manufacturers, competition, intellectual-property challenges and the need for future financing. The company also cautioned that macroeconomic conditions, inflation, interest rates and access to uninsured bank deposits could affect operations or liquidity.
- Management concluded that disclosure controls were effective at the reasonable-assurance level as of June 30, 2023, and reported no material changes to internal control over financial reporting during the quarter. The filing stated there was no substantial doubt about the company’s ability to continue as a going concern within one year of issuance.
Important facts for investors to verify
- Whether the stated cash runway into 2026 remains supportable as trial scope, enrollment, costs and financing needs evolve.
- Progress, safety, durability and final verified results from azenosertib trials, including the planned Phase 3 study and the Cyclin E1 biomarker strategy.
- Clinical progress for ZN-d5 and the BCL-xL degrader, and the cost and timing of their next development steps.
- The ultimate costs and obligations from the Zentera termination, including the contingent milestone and any future Greater China royalties.
- Cash burn, dilution from future equity financing, and the effect of the June offering on share count and per-share losses.